English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Can Psychedelics Help Fighters Heal Brain Trauma? Inside the UFC's New Research Push
A retired fighter forgets his own children's names. He gets dizzy walking across the kitchen. Last week, he says, is a blur. This isn't a scene from a documentary about boxing in the 1970s — it's the reality being described, right now, by men who fought professionally less than a decade ago. And it's the reality that has pushed one of the biggest combat-sports organizations in the world to start asking a question that would have been unthinkable a few years back: could psychedelics actually help? The UFC has quietly opened the door to exploring psychedelic-assisted therapy as part of its broader brain-trauma research, and the implications stretch far beyond the octagon. If plant medicine can offer something for fighters carrying years of accumulated damage, what does that say about the wider potential of substances most of the world still classifies as illegal? It's a strange moment in the story of psychedelics — one where the conversation has moved from underground ceremonies to press conferences with cage fighters. The shift didn't happen in a vacuum. For years, former fighters have spoken in hushed tones about cognitive decline, mood collapse, suicidal ideation, and the personality changes that often arrive in their forties. The condition has a name — chronic traumatic encephalopathy, or CTE — and it's a problem the sport has been slow to address publicly. When a recent feature documented one former UFC competitor's diagnosis of permanent disability, with memory loss severe enough that he sometimes forgets which child he's speaking to, the conversation got harder to dodge. UFC president Dana White acknowledged the obvious in a follow-up interview: this isn't one fighter's misfortune. It's structural. Anyone who has done this long enough is dealing with something. He called it part of the gig — which is honest, even if it's bleak. What's new is that the organization has signaled it wants to do more than nod sympathetically. A multi-year extension of its partnership with the Cleveland Clinic, plus a substantial donation to the Lou Ruvo Center for Brain Health in Las Vegas, set the stage. Then White name-dropped the psychedelic researchers at Johns Hopkins, and suddenly the story changed shape. The trigger appears to have been a televised feature on retired professional athletes — football players, mostly — who turned to psilocybin and ayahuasca after their careers ended. They described relief from depression, from rage, from the suffocating fog that follows years of head trauma. Their stories aren't peer-reviewed, but they're not nothing either. They're the kind of testimony that makes institutions pick up the phone. The Center for Psychedelic and Consciousness Research at Johns Hopkins has spent the last decade and a half building a serious body of work on substances like psilocybin and LSD. They've published dozens of peer-reviewed papers covering addiction (nicotine, alcohol, and other dependencies), end-of-life anxiety in cancer patients, and treatment-resistant depression. The results have been striking enough that the FDA has granted breakthrough-therapy status to psilocybin for depression, which is not the kind of designation a regulator hands out casually. What we don't yet have — and this is important — is a robust body of evidence specifically on psychedelics for traumatic brain injury. The mechanisms researchers are excited about are suggestive rather than proven. Psilocybin appears to promote neuroplasticity, meaning the brain's capacity to form new connections. Some animal studies have shown growth in dendritic spines after a single dose. For a brain that's been concussed dozens or hundreds of times, the idea of a compound that might literally help neurons reorganize is, understandably, electrifying. But excitement isn't proof. The leap from "helps depressed patients" to "repairs cumulative head trauma" is enormous, and any honest researcher will tell you we're nowhere near making it confidently. What's happening now is the early-stage work of asking whether the question is even worth pursuing. The fact that a major sports body is funding part of that question is itself remarkable. Step back from the UFC story for a moment, because something larger is going on. Across North America, attitudes toward psychedelics have shifted with surprising speed. Oregon legalized supervised psilocybin use. Several cities have decriminalized natural psychedelics. Veterans' groups have become unlikely advocates for ibogaine and ayahuasca, citing dramatic relief from PTSD that conventional medication never delivered. The conversation that lived in Amazonian ceremony huts and underground therapy circles is now happening in legislatures, hospitals, and yes, mixed-martial-arts boardrooms. The plants and compounds at the center of this shift are sometimes called master plants by the traditions that have used them for centuries — ayahuasca, peyote, San Pedro, iboga, certain mushrooms. The term carries a specific meaning: these aren't recreational substances in the cultures that birthed their use. They're considered teachers, agents that show a person something about themselves they couldn't otherwise see. Whether you take that framing literally or metaphorically, it points at something the clinical research keeps confirming — these compounds tend to produce experiences that feel meaningful, and that meaning seems to be part of why they work. For someone recovering from addiction, the experience often involves seeing one's relationship to the substance with terrible clarity. For someone in depression, it can briefly dissolve the walls that the depressed mind builds around itself. For someone carrying trauma — including, perhaps, the kind of trauma a fighter accumulates — it may offer access to material the conscious mind has buried. None of this guarantees healing. But it changes what's possible. If you're reading this because you've been quietly researching plant medicine for your own reasons — not because you fight professionally, but because something in your life has gotten stuck — the UFC story matters in an indirect way. Institutional interest tends to drag taboos into daylight. When a sports organization openly explores psychedelic therapy, it gives cover to the doctor who's been quietly curious, the therapist who has clients asking about it, the family member who didn't know how to bring it up. The conditions where psychedelics have shown the most consistent results in trials so far include: The picture that emerges from these studies isn't of a miracle drug. It's of a tool that, used in the right context with the right preparation and integration, can produce shifts that years of conventional treatment couldn't. The right context matters enormously. A psychedelic dose taken in a clinical or ceremonial setting, with trained support before and after, is a completely different experience from the same dose taken alone at a music festival. The compound is the same. The outcome rarely is. People reading articles like this one often have a quieter question underneath: should I actually do this? It's worth being honest about what a retreat involves, because the romanticized version doesn't survive contact with the reality. A real ayahuasca or psilocybin retreat is physically demanding, emotionally raw, and occasionally terrifying. Participants vomit. They cry. They confront memories they've spent decades avoiding. The cliché of "sitting with your stuff" is accurate, and the stuff is rarely pleasant company. What separates a well-run retreat from a risky one isn't the location or the marketing — it's the people running it and the support structure around the medicine. A few things worth checking before you commit: The cost varies wildly — anywhere from a thousand dollars for a short domestic retreat in places where local laws allow, to ten thousand or more for longer stays in Peru, Costa Rica, or Mexico with extensive medical support. Expensive isn't automatically better. Cheap isn't automatically suspect. What matters is the fit between what's offered and what you actually need. It's worth pausing on how unlikely this moment is. A combat-sports organization, a major medical research center, indigenous traditions from the Amazon, neuroscientists at a top-tier university, and ordinary people quietly weighing whether to book a retreat — all of them, in different ways, are circling the same question. What if the substances we've spent fifty years criminalizing turn out to be among the most useful tools we have for the things modern medicine struggles most with? The answer won't be a clean yes. It will be messy, partial, and full of caveats. Some people will be helped enormously. Others won't be helped at all. A few will have bad experiences that take years to integrate. This is true of every powerful intervention, from surgery to antidepressants to long-term therapy. What's different about psychedelics is that the conversation around them has finally caught up with what practitioners and participants have been quietly saying for decades — they do something, and that something is worth taking seriously. For readers who feel drawn to take this further — whether that means deeper reading, a conversation with a knowledgeable guide, or actually exploring a structured experience — a range of curated ayahuasca and psychedelic retreats can be browsed on our marketplace here. Whatever you decide, decide it slowly. The medicine isn't going anywhere, and the choice deserves the same care the experience itself will demand of you.
Oregon's Psilocybin Law: What Legal Mushroom Therapy Actually Looks Like
When Oregon voters approved Measure 109, something genuinely strange happened in American drug policy. A state had, for the first time, said yes to supervised, legal use of a classic psychedelic — psilocybin, the active compound in magic mushrooms — outside any research or religious-exemption framework. Not decriminalization. Not a clinical trial. An actual licensed-services model. If you're someone weighing a psychedelic retreat for depression, addiction, trauma, or just a stuck life pattern you can't seem to shake, this matters. It changes the map. I want to walk through what Measure 109 actually does, what it doesn't do, and how it fits into the bigger conversation around psychedelics, plant medicine, and addiction recovery. Because a lot of what gets repeated online is half right at best. The short version: roughly 56% of Oregon voters approved the measure. It directed the Oregon Health Authority to build a regulated program — the Oregon Psilocybin Services Program — where licensed facilitators can administer psilocybin to adult clients inside licensed service centers. Manufacture, processing, delivery, and possession of psilocybin became legal under state law, but only inside that licensed framework. Step outside it and the old criminal penalties still apply. The measure also baked in a two-year development period before the program actually opened its doors. That wasn't bureaucratic foot-dragging. Oregon was building something nobody else had built — licensing categories, training requirements, dosing rules, packaging standards, an advisory board, a tax structure. The state essentially had to invent the rulebook from scratch. A few specifics worth knowing if you're trying to understand what's actually on offer: The timing wasn't random. For most of the last decade, research out of Johns Hopkins, NYU, and Imperial College London has been publishing results on psilocybin-assisted therapy for treatment-resistant depression, end-of-life anxiety, and substance use disorders that ranged from interesting to genuinely startling. A single high-dose session, in the right setting, with proper preparation and integration, was producing sustained improvements that conventional pharmaceuticals struggle to match. That's the research backdrop. The cultural backdrop is messier and more interesting. A generation that grew up being told mushrooms would melt their brains started reading clinical papers and noticing the science said something rather different. Veterans were talking openly about psychedelic healing. People in addiction recovery were saying ibogaine and psilocybin had done what twelve-step rooms and SSRIs couldn't. The conversation around master plants — the term Amazonian traditions use for teacher-plants like ayahuasca, San Pedro, and tobacco — was bleeding into the mainstream wellness world. Oregon's vote was, in a sense, the political system catching up with what a lot of people had already quietly concluded: that these substances, used carefully, are not the menace the 1970s told us they were. Here's where I'll be honest with you. Oregon's program is real, and it's legal, and it's a meaningful option. But it's not the same animal as a traditional plant-medicine retreat in Peru or Costa Rica, and it's not trying to be. If you've been reading about ayahuasca ceremonies in the Sacred Valley or ibogaine clinics in Mexico, the Oregon model will feel different — more clinical, less ceremonial, English-speaking, regulated. Which one is right for you depends on what you're actually after. A few honest distinctions: Whether you end up in Oregon, in the Peruvian jungle, or at a psilocybin retreat somewhere in between, the same red flags apply. The legalization wave has brought in serious practitioners and also, frankly, a fair number of opportunists. A few things to look for, and a few to run from. Good signs: a thorough medical and psychological intake before you ever pay a deposit. Clear questions about your medications (especially SSRIs, MAOIs, and lithium — these interact badly with several plant medicines). A facilitator who's been doing this for years, not months. Real integration support, not a goodbye hug and a flight home. Honest conversations about who shouldn't take part — people with personal or family histories of psychosis, certain heart conditions, or untreated bipolar disorder are usually screened out for good reason. Warning signs: vague pricing, no medical questionnaire, promises of guaranteed healing, facilitators who claim to be the reincarnation of someone, group sizes that feel more like festivals than ceremonies, no aftercare plan, no way to talk to past participants. Trust your gut on this. The people doing serious work tend to feel grounded and a little boring in their professionalism. The flashy ones are often the ones to skip. One thing I'd offer to anyone reading this because they're hurting — because the depression hasn't lifted, because the drinking is back, because something inside is asking for help — is that psychedelics are a tool, not a magic eraser. The research is real. The experiences can be genuinely transformative. People do come out of a single session with shifts that years of talk therapy didn't produce. And. The work afterward is its own thing. The session opens a door. Walking through it — changing habits, repairing relationships, building the life the medicine showed you was possible — that part still belongs to you. The best retreats know this and structure their programs around it. The worst ones sell you the door and forget the rest of the house. If you're sitting with this decision, take your time. Read the research. Talk to people who've done it. Get medical clearance if there's any question. And if something here has nudged you toward exploring further, a curated selection of psilocybin and broader plant-medicine retreats can be browsed on our marketplace here. The right retreat at the right time can be a hinge in a life — but only if you walk in with eyes open.
Psychedelic Medicine in 2026: How MDMA, Psilocybin, and Ketamine Are Reshaping Mental Health
Something strange has happened to the conversation around psychedelics. A decade ago, mentioning that you were curious about psilocybin or MDMA at a dinner party got you a raised eyebrow and a quick subject change. Now your cardiologist might bring it up. Your therapist almost certainly has an opinion. And somewhere in the FDA's review pipeline, drugs derived from compounds your parents were told would melt your brain are quietly inching toward approval. If you're reading this because you're weighing a psychedelic retreat — for depression, addiction, trauma, or just the sense that something inside you needs reorganising — it helps to understand the broader picture. Plant medicine and psychedelics aren't fringe anymore. They're being studied in serious clinical trials, prescribed off-label in clinics, and discussed in medical journals that wouldn't have touched the topic in 2005. Here's where things actually stand. Ketamine was the one nobody expected to lead the charge. It's an anesthetic. A club drug. A horse tranquilizer, depending on who's telling the story. And yet it became the first compound to crack open mainstream psychiatry's door to dissociative and psychedelic-adjacent treatments — largely because its antidepressant effects refused to be ignored. What makes ketamine different from the SSRIs most people have tried (and many have quit) is the mechanism. Traditional antidepressants work on serotonin and take weeks to do anything noticeable. Ketamine acts on the glutamate system, and the relief can arrive within hours. For people who've been suicidal, that speed isn't a marketing point — it's the difference between making it through the week and not. By 2026, ketamine clinics have spread across most major cities in the U.S. and Europe. Spravato, the esketamine nasal spray, is FDA-approved for treatment-resistant depression and increasingly covered by insurance. The catch? Ketamine therapy isn't cheap, the effects can wear off, and it works best when paired with real psychological integration — not just an IV drip and a Lyft home. MDMA — the compound most people know as ecstasy or molly — has spent the last decade being studied in some of the most rigorous psychiatric trials ever run on a Schedule I substance. The work has been led primarily by MAPS, the nonprofit that's been pushing this research uphill since the 1980s. The results have been striking. In Phase 3 trials, a significant majority of participants with severe PTSD no longer met diagnostic criteria after a course of MDMA-assisted therapy. We're talking about combat veterans, survivors of childhood abuse, first responders — people for whom standard treatments had failed for years, sometimes decades. The therapy isn't a pill you take home. It's three or so dosing sessions in a clinical setting, paired with months of preparation and integration work. The FDA's review process has been bumpier than advocates hoped. There have been setbacks around trial methodology and concerns about therapist conduct in some sessions. Approval, when it comes, will likely arrive with strict guardrails — specific clinics, certified providers, monitored protocols. But the direction of travel is clear: MDMA is moving from underground use into supervised medical practice, and it's doing so faster than most psychiatrists predicted. If you've been following psychedelic research at all, you've probably seen the brain-scan images — the ones showing how psilocybin appears to loosen the rigid patterns of activity that depression carves into the mind. The research keeps replicating. Compass Pathways has moved psilocybin through multiple trial phases. Universities from Johns Hopkins to Imperial College London have dedicated entire research centres to the work. What's interesting isn't just the efficacy data — it's the patient stories. People describe a single high-dose psilocybin session producing more therapeutic movement than years of weekly talk therapy. That's a remarkable claim, and it deserves the skepticism it gets. But the data keeps showing the same thing: meaningful, durable reductions in depression scores, often after just one or two sessions. A few things worth knowing if you're considering a psilocybin retreat or eventually a clinical treatment: Ayahuasca sits in its own category, partly because its origins are nothing like the pharma-driven story of ketamine or MDMA. It's a brew. It's been prepared by Amazonian peoples for centuries. It contains DMT and an MAO inhibitor that makes the DMT orally active, and the experience tends to be longer, more physical, and more emotionally demanding than psilocybin. Clinical research on ayahuasca is real but smaller in scale than the work on psilocybin or MDMA. Studies out of Brazil and Spain have shown promising effects for depression and addiction, particularly for people who've cycled through conventional treatments without success. Anecdotally, the retreat circuit has been processing thousands of people a year for over a decade, and the patterns that emerge are consistent: ayahuasca tends to show people what they've been avoiding. Sometimes that's healing. Sometimes it's brutal. Often it's both. For addiction specifically, the picture is genuinely interesting. Ibogaine, derived from the iboga shrub, has shown remarkable results interrupting opioid dependency — and ayahuasca has its own track record with alcohol and stimulant patterns. Neither is a magic cure, and both carry medical risks that require real screening. But for someone who's tried twelve-step, rehab, SSRIs, and CBT without lasting change, plant medicine sometimes offers a doorway nothing else has. Here's the honest part. The legitimacy of psychedelic medicine is rising fast, but that doesn't automatically make every retreat a good idea. The same renaissance that's producing rigorous clinical trials is also producing a lot of opportunists — places that took a weekend training course and now call themselves a healing centre. If you're researching seriously, here are the questions that actually separate good operators from sketchy ones: You don't need every answer to be perfect. You do need to feel that the people running the place take the work — and your safety — seriously. A retreat that promises healing without acknowledging risk is a retreat to walk away from. What's actually happening, underneath all the headlines about FDA designations and Peter Thiel-backed startups, is a slow correction. For most of the last century, medicine treated the mind like a chemistry problem and the soul like a category error. Psychedelics — whether you encounter them in a clinic or a jungle — refuse that division. They make people feel things, see things, remember things. Sometimes they make people confront things they spent years avoiding. That's not a pharmaceutical pitch. It's an old observation that ceremonial cultures have known for a long time, and that Western science is now slowly, grudgingly catching up to. The medications coming out of clinical trials will help a lot of people. So will the retreats happening in Peru, Costa Rica, and the Netherlands. They're different doors into related territory. If something in this article has sharpened your curiosity, a curated selection of ayahuasca, psilocybin, and other plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision — this isn't a weekend you want to rush into, and the right container makes all the difference.
The Wall Street Bet on Short-Acting Psychedelics: What It Means for Patients
Picture a depression treatment that works in twenty minutes. Not weeks. Not a six-hour ceremony with a trained sitter and a playlist of Brian Eno. Twenty minutes, sublingual tablet under the tongue, back to your life by lunch. That's the bet a growing crowd of biotech venture capitalists is now placing on the next wave of psychedelics — and it's quietly reshaping what plant-medicine healing might look like for millions of people who never plan to set foot in a jungle. For the better part of a decade, most established healthcare investors stayed at arm's length from psychedelic startups. The science looked promising. The optics? Less so. But a handful of firms have stopped hedging, and the deals they're cutting tell you a lot about where mainstream medicine thinks this whole field is heading — and where it isn't. The first wave of publicly-traded psychedelic companies — think the ones developing synthetic psilocybin or pharma-grade ibogaine — chased the experience itself. Their drugs produced long, immersive sessions that required a trained therapist sitting bedside for four, six, sometimes eight hours. Beautiful in theory. A nightmare to scale. The new wave is different. Investors are now writing checks for compounds engineered around one ruthless question: how do you get the antidepressant effect without tying up a clinic room and a licensed practitioner for an entire afternoon? The answer, increasingly, is short-acting molecules — synthetic versions of 5-MeO-DMT (the famously intense compound found in certain toad secretions and Amazonian plants), or so-called non-hallucinogenic psychedelics that may rewire the brain without ever sending the patient on a trip at all. One Boston-based firm has been the loudest voice in this shift, putting money into a Dublin company working on a 30-minute-to-two-hour 5-MeO-DMT treatment for treatment-resistant depression, and another startup pursuing psychedelic-inspired drugs stripped of their hallucinogenic effects. More recently, the same investor incubated a new venture developing a sublingual 5-MeO-DMT tablet with effects expected to last just 15 to 20 minutes. That company launched with a $60 million Series A from a roster of mainstream healthcare funds — money that wouldn't have touched this space five years ago. Here's the uncomfortable math. A psychiatrist at a major academic center has estimated the U.S. might need tens of thousands of newly trained psychedelic-assisted therapists once these treatments hit the market. We don't have them. Training pipelines are years behind demand. And if every dose of psilocybin requires a six-hour appointment with two trained facilitators, the cost per patient quickly drifts into territory most insurance plans won't touch. So the investor logic goes like this: a 20-minute treatment fits inside an existing clinic visit. It can be administered by staff already on payroll. It doesn't require a special preparation week or a three-session integration arc. From a pure access standpoint — getting an effective treatment to the largest number of people — it's the difference between a boutique luxury and actual medicine. I'll be honest. Reading that, part of me cheers. Another part of me winces. Because the long sessions aren't just a logistical inconvenience — for a lot of people, the slow descent and the human presence are the medicine. Compressing the whole thing into a sublingual tablet may scale, but scaling and healing aren't always the same thing. If you're researching ayahuasca, ibogaine, or a psilocybin retreat right now — maybe because therapy hasn't worked, or because addiction has worn down everyone in your life including you — none of this biotech news is going to be available to you anytime soon. The clinical trials are early. FDA approval, if it comes, is years out. Insurance coverage is further still. In the meantime, retreats remain the only legal pathway in much of the world to access these compounds, and they offer something the pharmaceutical model probably never will: ritual, community, and time. That said, the pharma push matters even if you never take a clinical drug. Here's why: What it won't do is replace the retreat experience. A short-acting tablet in a beige clinic chair is not the same animal as three nights of icaros in a maloca, and anyone selling you on that equivalence is selling you something. This is the question I get asked the most, and the honest answer is: nobody fully knows yet. The master plants — ayahuasca, San Pedro, peyote, iboga — have been used in ceremonial contexts for centuries, sometimes millennia. The traditions around them include diet, song, prayer, and a relationship with a specific lineage. Strip out the alkaloid, synthesize it in a lab, deliver it in 20 minutes, and you have something pharmacologically similar but contextually unrecognizable. Some researchers argue the molecule does the heavy lifting and the ritual is decoration. Others — including a lot of facilitators who've sat with thousands of participants — would tell you the ritual is the medicine, and the compound is just the doorway. My read, after years around this work, is that both are partly right. The molecule opens something. What you do with what gets opened depends entirely on the container. A clinical setting offers safety, screening, and standardization. A traditional retreat offers depth, integration, and a framework of meaning that's hard to manufacture in a hospital. Different tools, different jobs. The mistake is pretending one makes the other obsolete. Of all the conditions being studied, addiction is where the case for psychedelic healing looks strongest — and where the gap between clinical trials and real-world need is widest. Ibogaine retreats in Mexico and Costa Rica have been quietly interrupting opioid addiction for years. Ayahuasca has a substantial body of evidence supporting its use for alcohol and stimulant dependence. Psilocybin trials at major universities have shown remarkable results for tobacco and alcohol use disorders. The biotech world is paying attention. But the drugs furthest along in trials are mostly aimed at depression and PTSD, because those markets are larger and the regulatory path is clearer. Addiction recovery — especially the kind that involves a long, difficult experience confronting your own patterns — may end up being one of the things the retreat world keeps doing better than the clinic, simply because the work doesn't compress neatly into 20 minutes. If you're reading this because addiction is the reason you're considering a retreat, a few honest things to keep in mind: The short version: the science is real, the money is finally flowing, and within the decade we'll probably have at least a few legal, clinically-approved psychedelic medicines. That's good news for access and good news for stigma. But it doesn't make the retreat tradition obsolete. If anything, the contrast between a 20-minute tablet and a multi-day ceremony will make people more aware of what each offers, and more able to choose the path that fits their situation. For some people, that path is a clinical trial. For others, it's months of preparation followed by a week in the Amazon. For a lot of folks, it's somewhere in between — microdosing, breathwork, integration circles, slow work over years. There's no single right answer, and anyone telling you otherwise hasn't sat with enough people on the other side of these experiences. If you're closer to the retreat end of the spectrum and want to see what's actually out there, a curated selection of ayahuasca, psilocybin, and plant medicine retreats can be browsed on our marketplace here. Take your time with the decision. The medicine isn't going anywhere, and the version of you that's ready will know when it shows up.
Silent Meditation Retreats: An Honest Guide for Curious Beginners
Sitting in silence for seven days sounds peaceful until you actually try it. Then the mind shows up — loud, opinionated, weirdly obsessed with a conversation you had in 2014 — and you remember why most of us fill every quiet moment with podcasts. A silent meditation retreat is a deliberate confrontation with that noise. Done well, it can quiet years of mental static. Done badly, or done too soon, it can rattle you in ways you didn't sign up for. This is the honest version of what a silent retreat is, what to expect, and how to figure out if you're ready for one — or whether you'd be better served by something else first. I write mostly about plant medicine and psychedelic retreats, and I bring that lens here on purpose: many people who land in ayahuasca or psilocybin ceremonies eventually find themselves curious about silent practice, and vice versa. The two paths talk to each other more than most people realise. A guided ten-minute sit on your phone is a snack. A silent retreat is a fast. The format itself is the medicine — no music, no soothing voice in your ear, no notifications, often no eye contact, no reading, no journaling for some traditions, no phone. Just you, a cushion, a schedule, and whatever your nervous system has been postponing. Most retreats sit somewhere on a spectrum. On one end, vipassana courses in the S.N. Goenka tradition run a strict ten days with two hours of sitting before breakfast and roughly eleven hours of practice total. On the other end, weekend retreats at insight meditation centres or Hridaya-style settings include some teachings, gentle movement, and a softer ramp into silence. Zen sesshins, Tibetan retreats, and Christian contemplative weeks each have their own flavour. Pick the wrong one for your temperament and you'll spend three days wondering if you've made a terrible mistake. The shared thread is that no one talks. Not at meals. Not in the hallways. Not even, ideally, with your eyes. The first time you eat a slow, silent dinner with thirty strangers, it feels comically awkward. By day three, it feels like the most natural way humans have ever shared a meal. Schedules vary, but the rhythm is recognisable across traditions. Here's a fairly typical retreat day, give or take an hour: Walking meditation matters more than people expect. After your third hour on the cushion, the slow, deliberate pace of a walking session feels like a gift from the gods. Meals, also — eating a single raisin for ten minutes sounds absurd until you do it and notice your jaw has been clenched for two decades. One thing newcomers underestimate: the boredom. Real, gnawing, almost physical boredom on day two or three. That's not a sign you picked the wrong retreat. It's usually the doorway. The mind exhausts its familiar entertainment loops and starts to settle into something quieter underneath. Silent retreats aren't for everyone, and certainly not for everyone right now. I'd push back gently on the idea that you should just leap into a ten-day vipassana because someone in your podcast feed said it changed their life. Some people genuinely aren't in a stable enough place for that much unstructured contact with their own psyche. A few honest questions worth sitting with before you book: None of these are dealbreakers in isolation. They're just signals worth taking seriously. A good teacher would rather you wait six months and come prepared than show up unready and get rattled. Here's where the worlds I usually write about start to overlap. A growing number of people come to silent meditation after a profound ayahuasca, psilocybin, or San Pedro experience, looking for a way to keep deepening the work without another ceremony. Others move in the opposite direction — they've sat through years of vipassana courses and find themselves curious about whether plant medicine might unlock something that pure silence hasn't. Both paths are valid, and they genuinely complement each other. Silent practice builds the capacity to be with what arises without flinching, which is exactly the skill that makes a difficult ceremony tolerable. A well-integrated psychedelic experience, in turn, can melt some of the defences that years of sitting have only nudged. Many seasoned meditators I've spoken with describe their first ayahuasca night as “twenty years of practice compressed into eight hours” — which is partly true and partly the kind of thing people say in afterglow. The honest version: psychedelics show you the territory; silence teaches you to live there. If you're using silent retreat as integration after a psychedelic experience, give yourself a buffer. Three to six weeks is a reasonable minimum. Walking straight from a Peruvian maloca into a ten-day vipassana is more than most nervous systems can metabolise gracefully. The silent meditation world is mostly trustworthy — many centres run on donations, the teachers tend to be career practitioners, and the lineages are well established. But it's not immune to bad actors or simply bad fits. A few practical filters: Cost varies wildly. Goenka vipassana courses are donation-based and astonishingly affordable. Insight Meditation Society and Spirit Rock in the US charge moderate fees with sliding scales. Boutique retreats in Bali, Costa Rica, or Tuscany can run well into four figures for a week. None of these tiers is automatically better than another — what matters is fit. Most retreats send a packing list. Read it. Then pack lighter than you think. A few things people consistently wish they'd brought: And leave the journal at home for your first one, unless the retreat explicitly invites journaling. The urge to write is often the mind's way of converting raw experience back into a story it can manage. Letting that urge pass unmet is part of the practice. The re-entry is strange. Speech feels loud and slightly fake for the first day. Driving feels insane. The supermarket — all that colour, all those choices — can knock you sideways. Some people cry in the car park. Some feel a quiet, settled clarity that lasts weeks. Some feel nothing for three days and then notice, gradually, that they're less reactive than they used to be. Whatever shows up, protect the transition. Don't book a red-eye flight the night your retreat ends. Don't schedule a tough conversation for the next morning. Give the new baseline a few days to settle into your normal life before you ask it to perform. If silence is what you're craving — or if you're looking for the contemplative ground to support deeper plant-medicine work down the line — a retreat is one of the most reliable investments you can make in your own inner life. For readers who want to take this further, a range of curated meditation and plant-medicine retreats can be browsed on our marketplace here. Either way, go in with realistic expectations, the right teacher, and a willingness to be bored. The rest takes care of itself.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Integrating an Iboga Experience: What Actually Happens After the Ceremony
Most people walk into an iboga ceremony bracing for the experience itself — the long hours, the visions, the physical weight of the medicine pressing them into the mat. What almost no one prepares for is what comes after. The ceremony ends. You go home. And then? Then the actual work starts. Iboga, the root bark from a small West African shrub used for centuries in Bwiti tradition, is one of the most demanding plant medicines on the planet. It's also one of the most studied for addiction recovery — particularly opioid dependency. But here's the thing nobody at the retreat will quite tell you straight: the medicine doesn't fix you. It shows you. What you do with what it shows you is the entire ballgame. There's a tempting story floating around the psychedelic healing space — that one heroic dose will rewire your brain, dissolve your addiction, and hand you back a new life. People do report dramatic shifts after iboga, especially around opioid cravings. That part is real. What gets glossed over is the window. After a flood dose of ibogaine or traditional iboga root bark, many people describe a period — sometimes called the gray day, sometimes stretching into weeks — where old cravings are quiet, old patterns feel optional, and the mind is unusually pliable. This isn't a permanent state. It's an opening. Treat it like a runway, not a destination. Without integration, that window closes and the old grooves reassert themselves. With integration, you can build new grooves while the soil is soft. The difference between people who hold their gains and people who relapse within six months is almost always what they did between week one and month six. Right after an iboga experience, you may feel clear in a way you haven't felt in years. Clean. Lucid. Convinced that everything has changed. That feeling is partly real and partly a chemical afterglow, and it's a terrible time to make big decisions. People in this phase quit jobs, end relationships, move countries, announce sweeping life pivots — and a fair number regret it three months later when the high tide of insight has receded and they're left looking at the wreckage. The medicine showed you something true, probably. But truth and timing are different animals. Move slowly. Eat real food. Walk outside. Write things down before you forget them, because you will forget them. Integration isn't a mystical process. It's mostly mundane, daily, and a bit boring — which is exactly why people skip it. Here's what tends to work, drawn from what facilitators and people who've sustained their changes actually do. For the first week, sit down every morning and write whatever you remember. Visions, conversations with whatever you encountered, body sensations, names of people who appeared, regrets that surfaced. Don't edit. Iboga insights have a strange half-life — vivid for ten days, then they start dissolving. The journal is your archive. Talking to people who haven't done plant medicine about a plant medicine experience is mostly frustrating. They'll either be politely baffled or quietly worried about you. Find one person — a facilitator who offers integration calls, a therapist trained in psychedelic integration, a peer from your retreat — who can hear what you're saying without translating it into something smaller. One real conversation beats ten polite ones. Iboga tends to show people a long list of things that aren't working. Trying to fix all of them at once is how people burn out and end up back where they started. Choose one. Maybe it's the relationship you keep avoiding. Maybe it's the substance you keep returning to. Maybe it's the work schedule that's been quietly killing you. One thing, attacked seriously, will do more for you than ten things attacked half-heartedly. Iboga is a deeply somatic medicine — it lives in the body for a long time, and the insights it surfaces are often stored in the body too. Some kind of regular physical practice helps the integration land: walking, swimming, yoga, breathwork, simple stretching. Nothing extreme. The goal is to stay in contact with yourself, not to optimize a fitness routine. Ibogaine has a serious track record in interrupting opioid dependency. Clinics in Mexico, Costa Rica, and a handful of other jurisdictions have been treating heroin and prescription opioid addiction with it for decades, and the published outcomes are interesting enough that mainstream addiction medicine is finally paying attention. But interrupting is not the same as curing. What ibogaine seems to do reliably is take away the acute withdrawal and reset cravings for a window of time. What it cannot do is rebuild the life you'll re-enter once that window opens. If you go back to the same apartment, the same friends, the same patterns, the same unaddressed trauma — the addiction will find its way home. The people who stay clean after iboga are almost always the ones who treated the medicine as the start of a long process, not the end of a short one. This is why reputable iboga providers increasingly insist on aftercare programs, sober living arrangements, and structured follow-up. If you're considering iboga for addiction and the retreat you're looking at doesn't ask hard questions about your plan for the weeks after — that's a red flag worth paying attention to. A few patterns show up over and over with people who lose ground after an iboga journey: Iboga can surface old material — trauma, grief, suppressed memories — that doesn't always tuck itself back in neatly. Most people handle the unpacking with journaling, peer support, and time. Some people need more, and there's no shame in that. If you're experiencing prolonged sleep disruption past a few weeks, intrusive memories that won't settle, depressive episodes deeper than your baseline, or thoughts of self-harm, that's the moment to find a therapist — ideally one familiar with psychedelic integration, though a competent trauma therapist of any stripe is better than going it alone. Iboga can crack things open that need a professional hand to help close. Plant medicine doesn't replace mental health care. At its best, it accelerates and deepens the work. At its worst, it surfaces things you weren't ready to face. Knowing the difference, and being willing to ask for help, is part of being a serious participant in your own healing. People who've held their iboga insights five and ten years later describe something interesting: the experience itself becomes less central over time, but the small daily decisions they made in the months after — the boundary they finally drew, the job they finally left, the practice they finally committed to — those compound. The ceremony was a doorway. The life on the other side was built one ordinary week at a time. That's the part the brochures don't sell well, because it isn't dramatic. But it's the part that matters. If you're seriously considering iboga for addiction, depression, or a stuck pattern you can't seem to shake, the question to sit with isn't whether the medicine will work. It's whether you're prepared to do the slow, unglamorous work that makes the medicine stick. For readers who want to take this further, a range of carefully vetted iboga and ibogaine retreats can be browsed on our marketplace here. The plant will do its part. The rest is yours.
Why Silicon Valley Founders Are Flying to Peru for Ayahuasca Ceremonies
Somewhere in the Sacred Valley of Peru, between Cusco and Machu Picchu, an adobe temple sits on a ridge overlooking the Andean highlands. Inside, a group of founders — people who normally spend Tuesday mornings arguing about runway and burn rate — are lying on thin mats, waiting for a brew of bitter brown liquid to start dismantling everything they think they know about themselves. This is what an ayahuasca retreat for tech entrepreneurs actually looks like. And it costs roughly the price of a decent used car. The trend isn't new anymore — it's been simmering for over a decade — but the questions around it have only sharpened. Why are so many high-functioning, ambitious people turning to plant medicine? What does it actually do? And is it a legitimate tool for working through stuck patterns, including addiction and burnout, or just the latest expensive thing successful people do to feel something? I've sat in enough ceremonies and interviewed enough facilitators to have opinions on all of that. Let's get into it. The pattern goes back further than most people realize. Steve Jobs talked about LSD as one of the most important experiences of his life. Bill Gates dabbled. Tim Ferriss has been openly discussing psychedelics for years, once comparing ayahuasca in tech circles to grabbing coffee. That's an overstatement — you're not going to find anyone microdosing DMT between standups — but the cultural underground is real. What changed around the mid-2010s was the appearance of structured programs aimed specifically at founders and executives. One of the better-known ones runs small cohorts to Peru each year — usually around 20 people split across two trips, drawn from hardware, software, and fintech startups. The price tag tends to land between $10,000 and $12,000 once you factor in coaching, lodging, ceremony, and the long-haul flights. The founder of one such program once put it bluntly to a reporter: you can spend six years in therapy, or you can spend ten days in the Andes. Red pill or sugar pill? It's a great soundbite. It's also, in my honest opinion, only half true. More on that later. The brew itself is made from the Banisteriopsis caapi vine, often combined with chacruna leaves that contain DMT. Indigenous peoples across the Amazon have been working with this combination for centuries — some traditions say thousands of years — as part of healing and spiritual practice. It's legal in Peru and in a handful of other South American countries. In the United States it sits in a strange grey zone: DMT is Schedule I, but two religious organizations have won the right to use the brew sacramentally. A typical 10-day retreat tends to follow a rhythm something like this: Inside the ceremony itself, the experience varies wildly. Some people describe lucid-dream-like visions — wandering through landscapes, encountering animals, replaying childhood scenes. One past participant of a tech-focused retreat described witnessing himself as a boy in a humiliating moment from grade school and finally, at age forty-something, deciding to put the shame down. Another described leaving her body entirely and watching herself from across the room. A friend of mine swears he spent two hours moving through what he insists was the inside of his own digestive tract, like a deranged children's TV episode. And then there's the vomiting. Almost everyone purges. Practitioners call it cleansing; your body calls it Tuesday. A well-run ayahuasca ceremony has buckets, towels, and absolutely no judgment about any of it. This is the question that brings most thoughtful people to plant medicine in the first place — and it deserves a careful answer. There's a growing body of clinical and observational research suggesting that ayahuasca, psilocybin, and ibogaine can produce meaningful, sometimes durable shifts in people struggling with depression, PTSD, alcohol use disorder, and opioid dependence. Ibogaine in particular has a long track record with opioid addiction — it appears to reset some of the neurochemistry involved in withdrawal and craving. Ayahuasca's effects on addiction seem to work through a different door: not by interrupting the chemistry directly, but by surfacing the emotional material that drives the behavior in the first place. That said — and this matters — psychedelics are not magic. They don't do the work for you. What they do is create an unusual window in which patterns become visible, often painfully so. What you do with that visibility afterward is the actual healing. Facilitators have a word for this: integration. It's the part where you come home, talk through what surfaced with a therapist or coach or trusted friend, and start translating insight into different daily behavior. Skipping integration is the most common mistake I see. People take the trip, have a profound night, fly home, and then six months later wonder why nothing actually changed. The ceremony was the easy part. Let's talk honestly about money, safety, and quality — because this is where retreat-seekers most often get burned. Costs for a reputable ayahuasca retreat in Peru typically range from about $1,500 for a basic week with a local center to $11,000 or more for a high-touch program with executive coaching wrapped around it. Neither extreme is automatically better. I've sat in ceremonies at modest centers run by lineage shamans that were more rigorous and more healing than fancy operations with infinity pools. Price signals nothing in this world. What you actually want to evaluate: The unflattering nickname for sloppy, poorly run ceremonies is “yogahuasca” — a Bay Area knockoff aesthetic stapled onto a sacred practice. The problem isn't confined to California either. As demand has exploded, some operations in Peru have followed the money rather than the lineage. Caveat emptor applies, hard. Plant medicine isn't for everyone, and I'd argue strongly against the “hack your consciousness” framing that tech culture sometimes wraps around it. This isn't a shortcut. It's a serious encounter with your own mind, and the people who get the most from it tend to share a few traits. They've usually tried other things first — therapy, meditation, hard conversations, time off. They have a baseline of psychological stability and aren't in active crisis. They have someone to talk to when they get home. They approach the experience with respect rather than treating it as a novelty item to collect alongside Burning Man and a Wim Hof workshop. And critically, they're willing to sit with discomfort. Ayahuasca isn't fun. It's revelatory, sometimes beautiful, occasionally terrifying, and almost always physically rough. People who want pleasant trips should look elsewhere. The founders I've spoken to who report the most lasting benefit describe specific behavioral changes afterward — quitting jobs that were wrong for them, restructuring how they interact with employees, finally addressing a drinking habit, ending relationships that had been quietly dying for years. The shift isn't mystical. It's that the ceremony made a long-avoided truth impossible to ignore for one night, and they found the nerve to act on it. If you've read this far and you're still curious, a few practical suggestions before you book anything. Read at least three first-person accounts of difficult ceremonies, not just the glowing ones. Talk to someone who's been. If you're on prescription medication, especially antidepressants, consult with a doctor who actually understands plant medicine — not all of them do. Sit with the question of why you want to do this. “To see what it's like” is a fine answer for a wine tasting; it's a thin reason to invite an Amazonian vine into your nervous system for six hours. Give yourself a clear week on the back end with no major commitments. The landing is real, and trying to jump straight into a board meeting after a retreat is how people lose the insights they came for. Find a therapist or integration coach you trust, ideally before you go. For readers who want to take this further, a range of vetted ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, decide it carefully — this is one of those choices that tends to matter more in the months after than in the moment you book it.
Silent Meditation Retreats: An Honest Guide to Sitting in Stillness
How much actual silence have you had today? Not background-music silence. Not nobody-is-talking-but-the-phone-is-buzzing silence. Real, uninterrupted quiet — the kind where you can hear yourself blink. For most of us, the honest answer is: almost none. We move through days stitched together by notifications, podcasts, traffic, group chats, and the low hum of our own running internal monologue. After enough years of that, the nervous system forgets what stillness even feels like. Which is probably why you ended up here, reading about silent meditation instead of doom-scrolling. This is a practical guide. What silent meditation actually is, where it came from, what happens in your head during a long sit, and what to expect if you decide to book a silent retreat. I'll be honest about the uncomfortable parts too, because the glossy version doesn't help anyone make a real decision. The phrase sounds redundant. Isn't all meditation silent? You sit, you close your eyes, you breathe. Quiet by definition, right? Not quite. A lot of what gets called meditation today is guided — a teacher's voice, a soundtrack, a body-scan recording on an app. Useful, especially for beginners, but it's a different beast. Silent meditation is the unguided cousin. No voice. No music. No bells (well, sometimes one bell to mark the start and end). Just you, your breath, and whatever your mind decides to throw at you. That last part is the catch. The silence on the outside reveals how loud it is on the inside. People who try a serious silent sit for the first time are often shocked by the sheer volume of mental chatter. The practice isn't really about achieving silence — it's about being still enough to notice everything that isn't. There's a useful middle ground worth knowing about. Semi-guided sessions bookend silence with brief instruction — a teacher sets an intention at the start, lets you sit for thirty or sixty minutes, then closes the session with a few words. This is how a lot of beginners ease in. Fully unguided is the traditional form: you arrive, you sit, time passes, you stand up. No one tells you when to focus on your breath or whether you're doing it right. That's both the freedom and the difficulty of it. Silent meditation isn't a wellness trend. It's roughly two and a half thousand years old, with roots in the Buddhist tradition of Vipassana — a word that translates loosely as seeing things as they really are. After the Buddha's enlightenment, he spent the rest of his life teaching variations of this technique across what's now northern India. The practice nearly disappeared from India over the centuries that followed but was preserved, almost by accident, in Burma (now Myanmar). In the twentieth century, a Burmese-Indian teacher named S.N. Goenka brought a stripped-down, secular version back to India and then to the West. The ten-day silent Vipassana retreats people talk about today — the ones with no talking, no phones, no eye contact, no reading — descend directly from that lineage. You can read more about the tradition on Wikipedia's entry on Vipassanā if you want the longer history. This matters because it tells you something about what you're walking into. Silent meditation wasn't designed as a stress-management tool. It was designed as a path toward understanding the nature of the mind. The fact that it also lowers cortisol and helps people sleep better is, in the original framing, almost a side effect. Here's what the brochures rarely spell out: the first two or three days of a silent retreat are often miserable. Not in a dramatic way. In a quiet, gnawing, oh-god-what-have-I-done way. The schedule is brutal by modern standards. Wake-up bell around 4 a.m. Sitting sessions of an hour or longer, repeated through the day, with breaks for simple vegetarian meals and walking. No talking to other students. No journaling. No music. Your phone is locked away. By day two, your knees hurt, your back hurts, and your mind has started serving up every unresolved memory it can find, like a search algorithm that finally got some bandwidth. And then — usually somewhere between day three and day five — something shifts. The chatter doesn't stop, exactly, but you stop being so identified with it. You notice a thought arise and pass without chasing it. You feel a sensation in your shoulder and don't immediately need to interpret it. The shoulders themselves drop a little. You start to understand, in a felt way rather than a conceptual one, what teachers mean when they talk about awareness. What people typically report after a silent retreat: I'll be direct. Long silent retreats are not the right starting point for everyone. If you're in the middle of an acute mental-health crisis, recently bereaved, or working through unprocessed trauma without any therapeutic support, ten days alone with your mind can do more harm than good. Reputable retreat centers will sometimes screen for this. Less reputable ones won't. This is also worth saying given who tends to read posts like this: silent meditation and plant medicine sit in adjacent neighborhoods of the inner-work world, and people often consider both. They do different things. A psychedelic ceremony tends to crack you open quickly; silent meditation teaches you, slowly, how to live inside the opening. Many of the most grounded plant-medicine practitioners I know also sit regularly. The two practices feed each other, but neither is a substitute for the other. Silent retreats vary enormously. Some are donation-based and run by experienced lineage teachers. Some are five-star resort experiences with optional silence. Both can be valuable; they're just different products. A few things worth asking before you book: Cost varies wildly. Donation-based Vipassana courses in the Goenka tradition are genuinely free at point of entry, supported by past students. Boutique silent retreats in places like Bali, Costa Rica, or the south of France can run several thousand dollars for a week. Neither pricing model is automatically better; the question is what fits your situation and what kind of container you need. You don't need to fly anywhere to find out whether this practice resonates. Try sitting in unguided silence for twenty minutes a day for two weeks. No app, no music, no podcast. Set a timer, find a spot, watch your breath, and notice what your mind does. If after two weeks you're still curious — even if you're also frustrated — that's a good sign. A retreat will deepen what's already begun. If after two weeks you feel only resistance and nothing else, that's also useful information. Maybe the timing isn't right, or maybe a guided practice or a different modality is a better entry point. There's no rule that says silent meditation has to be your path. For readers who feel ready to take this further, a range of meditation and contemplative retreats — including silent sits and integration-focused programs — can be browsed on our marketplace here. Take your time choosing. The right container makes an enormous difference, and the silence will still be there when you're ready for it.
Santa, Shamans, and Fly Agaric: The Psychedelic Roots of Christmas
Picture a man in red and white robes, sliding down through a hole in the roof in the dead of winter, leaving gifts beneath an evergreen tree. Sounds like Santa. It also sounds suspiciously like a Siberian shaman on a heavy dose of Amanita muscaria — the fly agaric mushroom that grows at the base of pines and birches across the northern hemisphere. The overlap between this peculiar fungus and our modern Christmas iconography is one of the stranger threads in the broader story of psychedelics and human culture, and once you start pulling on it, the whole sweater of holiday tradition begins to unravel in interesting ways. This isn't fringe internet conspiracy — at least not entirely. Ethnobotanists have been writing about the connection for decades, and while no one can prove a direct line from a Koryak shaman in the 1600s to the Coca-Cola Santa of the 1930s, the parallels are hard to wave away as coincidence. So pour yourself something warm and let's wander through the evidence. The short version: among the Koryak, Kamchadal, Evenki, and other Indigenous peoples of the Russian Far East and Siberia, the fly agaric was — and in some communities still is — a sacred psychoactive. Shamans used it as a tool for divination, especially around the winter solstice, when daylight bottoms out and the new solar year begins to claw its way back. They reportedly dressed in red and white to mirror the mushroom's distinctive cap. They entered yurts (round felt tents) through the smoke hole at the top, because the snow blocked the regular door. They distributed mushrooms as gifts. They spoke of flying through the night sky toward the North Star to gather wisdom for the coming year. Read that paragraph again and tell me you don't see Santa squinting back at you. The red suit. The chimney entry. The sleigh ride. The annual visit on the longest night. None of this is a smoking gun on its own, but the cumulative weight starts to feel like more than a stretch — especially once you bring the reindeer in. Before going further, it's worth being clear-eyed about what Amanita muscaria actually is. It's a mycorrhizal fungus that grows in symbiosis with the roots of certain trees — birch, pine, spruce — which is why it can't be cultivated commercially and has to be foraged. It contains two main active compounds: ibotenic acid and muscimol. Ibotenic acid is essentially the prodrug; the body slowly converts it into muscimol, which is the compound responsible for the bulk of the experience. Importantly, fly agaric is not a classic psychedelic in the way psilocybin mushrooms or ayahuasca are. It doesn't act on serotonin 5-HT2A receptors. Instead, muscimol is a GABA-A agonist — it works on the same receptor system as alcohol and benzodiazepines, just from a very different angle. The result is something more dreamlike, dissociative, and unpredictable than a typical psilocybin journey. Reported effects include: Effects typically peak around three hours in and can last anywhere from ten to twenty-four hours. The raw mushroom is genuinely toxic and people do get seriously sick from eating it improperly. Traditional preparation — drying, repeated boiling, or the rather notorious reindeer-urine method — converts most of the ibotenic acid to muscimol and reduces the worst side effects. This is not a casual snack. The reindeer connection is where the story gets gleefully strange. Reindeer in Siberia love fly agaric. They seek it out, dig it from beneath the snow, and eat it apparently for its psychoactive effect. They tolerate the toxins in ways humans don't. The herders noticed this. They also noticed something else: the muscimol passes through the reindeer's body largely intact and ends up in the urine. So — and there's no polite way to say this — people drank the urine. Either straight from the snow or collected from the animal directly. It was a brilliant pharmacological hack: the reindeer's metabolism filtered out most of the nasty stuff, leaving a relatively cleaner psychoactive product. Some accounts even describe the urine being passed from person to person, with muscimol staying potent through several recyclings. Once you know this, the image of reindeer prancing through the sky with a slightly delirious-looking man in red takes on a whole new dimension. And Rudolph's glowing red nose? Probably a stretch — but the most famous red thing in the snowy north, the thing that made reindeer matter to these cultures in the first place, was a mushroom with a bright red cap. Make of that what you will. The Christmas tree is one of the most curious customs in the Western calendar. Why drag an evergreen indoors in December? Pre-Christian solstice traditions across northern Europe revered evergreens as symbols of life persisting through winter death, and that's the standard explanation. But there's a more specific reading too. Fly agaric only grows beneath certain trees — pines, birches, spruces — because it needs their roots to survive. In Siberian cosmology, these trees were sometimes seen as cosmic axes connecting earth to sky, and the mushrooms that appeared beneath them were considered gifts from the tree itself. Foragers would gather them from under the branches, much the way children today gather presents from under a decorated fir. The drying process adds another layer. To reduce toxicity, the mushrooms were often hung from tree branches to dry in the cold winter air. Bright red caps dangling from evergreen boughs. Sound like ornaments yet? Other accounts mention drying them in stockings hung above the fireplace, the heat slowly removing moisture without cooking off the active compounds. Stockings by the fire. On the longest night of the year. Waiting for something. As these traditions drifted west and tangled with Norse and Sami practice, new versions emerged. There's a thread in Nordic folklore involving Odin riding the night sky on his eight-legged horse Sleipnir during the midwinter Wild Hunt. In some tellings, blood or saliva dripped from the horse's mouth as it galloped, and where those droplets fell, fly agaric mushrooms grew the following season. Eight reindeer. Eight-legged horse. Probably not unrelated. The Sami of northern Scandinavia, who herd reindeer to this day, had their own shamanic traditions involving fly agaric. Their drums were sometimes painted with the mushroom's image. Their noaidi (shamans) wore red and white. Their cosmology mapped neatly onto solstice timing. As Christianity spread north and absorbed local custom — as it almost always did — these elements didn't disappear; they simply got reassigned. Here's where I have to be honest with you. The fly-agaric-equals-Santa theory is popular, it's fun, and parts of it are well-documented. But it's also been disputed by serious scholars. The historian Ronald Hutton, who knows more about British and northern European folk tradition than almost anyone alive, has pushed back on the strongest versions of the claim. He argues that fly agaric use was less widespread than the popular story suggests, that Siberian shamans didn't dress in red and white as a uniform, and that the modern Santa is mostly a product of nineteenth-century American writers and illustrators — Clement Clarke Moore, Thomas Nast — drawing on Dutch Sinterklaas traditions. That's a fair correction. The Coca-Cola red-suit Santa really did come from a 1930s advertising campaign, even if the colour scheme already existed in earlier illustrations. Saint Nicholas of Myra was a real fourth-century bishop with no obvious mushroom connections. And a lot of the more specific claims — about chimneys, about reindeer urine, about gifts under trees — get sharper and more dramatic each time they're retold online. The reasonable middle ground goes like this: Siberian and northern European peoples did use fly agaric ceremonially. Their solstice practices did involve reindeer, evergreens, red-and-white symbolism, and ecstatic flight. These traditions did drift south and west over centuries, mingling with Christian and folk customs. Whether they directly shaped Santa Claus is unprovable — but to say they had zero influence on the broader symbolic vocabulary of midwinter celebration feels equally unsupportable. Fly agaric is having a quiet moment. As psilocybin and ayahuasca have moved into mainstream conversation, Amanita muscaria has crept along behind them, partly because it occupies a strange legal grey zone in many countries — unlike classic psychedelics, it isn't scheduled in most of the US, the UK, or the EU. You can find it sold openly, sometimes in gummies or tinctures, which is not the same as saying it's a good idea to use it casually. It's a different animal from the serotonergic psychedelics most retreat-seekers are researching. The experience is harder to predict, the dose-response curve is steeper, and the risk of an unpleasant or genuinely toxic episode is real. People who work with it traditionally do so with deep knowledge of preparation methods passed down through generations. Most of us don't have that. If you're curious about plant medicine for healing addiction, depression, or trauma, fly agaric is probably not the first door to open — ayahuasca, psilocybin, and ibogaine all have substantially more clinical research and a much longer track record of facilitated, ceremonial use in modern retreat settings. Still, the mushroom matters culturally. It's a reminder that the human relationship with master plants and psychoactive fungi is ancient, that it's woven into rituals we still perform without realising what we're doing, and that the line between religion, medicine, and altered states has always been blurrier than tidy modern categories suggest. If your interest in psychedelics is partly a search for older, deeper ways of marking time and meaning, a range of ayahuasca, psilocybin, and other plant-medicine retreats can be browsed on our marketplace here. Whether or not Santa is a Siberian shaman in disguise, there's something worth holding onto in the story. Midwinter is when human beings have always reached for the strange — for ritual, for light in the dark, for some hint that the year is going to turn and the sun will come back. That instinct predates Christianity, predates Coca-Cola, predates the mushroom theory itself. It probably predates language. So this December, when you string up red and white ornaments and hang stockings by a fire and put presents under an evergreen tree, you might be participating in a tradition far older and weirder than the carols suggest. Worth a quiet nod to the reindeer, at least.
MDMA-Assisted Therapy for Autism and Social Anxiety: What the Research Suggests
Social anxiety isn't shyness. Anyone who's lived inside it knows the difference — the racing pulse before a dinner party, the rehearsed sentences that never quite leave your mouth, the exhaustion of pretending you're fine. For many autistic adults, that experience runs deeper still. Reading a room, parsing tone, tracking the unspoken rules of small talk — these things cost energy most people never have to spend. And the standard treatments? They don't always help. Which is why a study published in the journal Psychopharmacology caught the attention of researchers, clinicians, and a lot of curious readers. The trial was small. The conditions were tightly controlled. But the results hinted at something the psychedelic-therapy field has been quietly building toward for years — that MDMA, used in a clinical setting with trained therapists, might offer real relief for autistic adults living with severe social anxiety. Researchers at the Biomedical Research Institute at Harbor-UCLA Medical Center ran a trial with twelve autistic adults. Half received two MDMA-assisted therapy sessions; half received placebo paired with the same therapeutic structure. Everyone was assessed using the Liebowitz Social Anxiety Scale, a clinical tool that produces a numeric score — higher means more socially anxious. The MDMA group saw an average drop of 44.1 points on the scale. The placebo group dropped 19.3. That's a meaningful gap, especially in a population for whom conventional anti-anxiety medications and talk therapy often fall short. Participants didn't just score lower on a questionnaire — they described feeling, sometimes for the first time, that interacting with other people wasn't a battle to be survived. One participant said they felt as though they were experiencing their best self and seeing the world clearly for the first time. Another talked about realizing communication wasn't only about talking — that emotions, theirs and others', deserved attention before words did. These aren't the kinds of statements a placebo response usually produces. MDMA isn't a classical psychedelic in the way psilocybin or LSD are. It's an empathogen — a compound that increases feelings of trust, emotional openness, and connection. In a therapeutic context, that pharmacology is the point. The drug doesn't do the work; it lowers the walls so the work can happen. Therapists guide the session. The medicine softens the defenses that usually keep painful or confusing material out of reach. For autistic adults whose social anxiety is rooted in years of misread cues, social rejection, or trauma from being forced to mask, that softening can be the door. The therapy team in the Harbor-UCLA study reported no unexpected adverse reactions. Side effects matched what's been seen in other MDMA trials — fatigue, headaches, sensitivity to cold — and none were serious. Charles Grob, one of the study's authors, pointed to something the numbers don't quite capture: participants showed up to social situations afterward with more self-confidence. The settings that used to overwhelm them felt navigable. That's the kind of outcome that matters in a life, not just a paper. This work doesn't exist in a vacuum. Over the past decade, MDMA-assisted therapy has produced some of the strongest clinical results in any mental-health research program. The Multidisciplinary Association for Psychedelic Studies (MAPS) has shepherded MDMA through Phase 3 trials for PTSD, where the majority of participants in some studies no longer met diagnostic criteria after treatment. Psilocybin has shown promise for treatment-resistant depression. Ibogaine and ayahuasca are being studied for addiction and trauma. Ketamine clinics have proliferated across the U.S. Within that picture, the autism study is small but conceptually important. It expands the conversation beyond PTSD and depression. It suggests psychedelic-assisted therapy might be useful for populations that traditional psychiatry has often failed — not by curing autism (it's not a disease to cure) but by addressing the secondary anxiety that years of social difficulty can produce. It also raises uncomfortable questions for the field. Autistic adults are an underserved research population. Sample sizes are tiny. Funding is hard to find. The researchers behind the Harbor-UCLA work have been clear that they hope their paper sparks larger trials. A few things worth saying plainly, because the psychedelic conversation gets hyped fast. The honest framing: this is early evidence that points somewhere worth going. It's not a green light for self-treatment, and it's not a promise of healing. It's a reason to pay attention to where the science is heading. A lot of readers who follow MDMA research also find their way to ayahuasca, psilocybin, and other plant medicines used in retreat settings. The mechanisms differ. The traditions differ. But the underlying intuition is similar — that certain substances, in the right container, with the right preparation, can help people contact parts of themselves that ordinary life keeps locked away. Ayahuasca ceremonies, in particular, have drawn autistic adults and people with severe social anxiety to retreat centers in Peru, Costa Rica, and elsewhere. The reports are mixed and personal — some find profound shifts in how they relate to others; some find the intensity overwhelming. There's no clinical equivalent of the Harbor-UCLA study for ayahuasca and autism yet, and the small but vocal community of autistic ayahuasca participants tends to emphasize that preparation, facilitator skill, and aftercare matter enormously. If you're someone considering a retreat partly because social anxiety has shaped your life in painful ways, a few things are worth weighing carefully. Talk to your doctor, especially if you take SSRIs or other psychiatric medications — interactions with MDMA, ayahuasca, and similar substances can be serious. Ask retreat centers specifically about their experience with neurodivergent participants. Read the integration plan, not just the brochure. Alicia Danforth, one of the study's co-authors, has been working in this area for years and has spoken about wanting their paper to attract funding for larger trials. That's the bottleneck. Psychedelic research is expensive, slow, and politically fragile. Studies involving autistic adults face additional ethical scrutiny — appropriately so. But the pilot data is now on the record. Other research groups are paying attention. The broader MDMA-therapy program continues to move toward formal approval in the U.S., with regulatory decisions on PTSD treatment shaping what's possible for other indications. If MDMA-assisted therapy becomes a legal clinical option for PTSD, the path for studying it in other anxiety conditions — including social anxiety in autistic adults — gets a lot shorter. For now, the takeaway is modest but real. Twelve people sat through two carefully structured sessions with a compound that most of Western medicine spent forty years calling worthless, and they came out the other side describing social ease they hadn't felt before. That deserves more research, more funding, and more honest conversation about who psychedelic therapy could actually help. If something in this conversation speaks to you, the broader landscape of psychedelic and plant-medicine retreats can be browsed on our marketplace here — a useful place to start if you're researching options with an open mind and a careful one.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
